Disc Medicine, Inc.
NASDAQ:IRONBiotechnology
-$0.02 today
- Market cap
- $2.99B
- Beta
- 2.10
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$6.28
Volume 0.95M
Average 0.47M
IRON Deferred Income Tax
The difference between tax expense recognized and tax actually paid in cash during the period.
Disc Medicine, Inc.NASDAQ: IRON
Deferred Income Tax · Q3 FY2026 · quarter ended Sep 2026
Deferred income tax outflow grows to $0
Q3 FY2026 deferred income tax was $0, compared with $0 a year earlier. Trailing-twelve-month deferred income tax was $0.
Context
- Deferred income tax increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly deferred income tax holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Deferred Income Tax history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Deferred Income Tax | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Deferred Income Tax vs competitors
How IRON compares with its peers on the latest reported figures
- IRON's LTM Sep 2026 deferred income tax of $0 is the largest of the 6 companies compared; the peer median is $0.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
IRONDisc Medicine, Inc. | LTM Sep 2026 | $0 | — | — | — |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
COAGHemab Therapeutics Holdings, Inc. Common Stock | FY2025 | $0 | — | — | — |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
DMRADamora Therapeutics, Inc. | LTM Jun 2024 | $0 | — | — | — |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding IRON) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for IRON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (35.97M) | (46.83M) | (76.43M) | (109.36M) | (212.18M) |
| Depreciation & Amortization | 32K | 89K | 100K | 156K | 281K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 507K | 2.09M | 5.53M | 16.82M | 34.34M |
| Change in Working Capital | 1.29M | 2.13M | (2.95M) | 3.23M | 3.53M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.32M | 526K | (3.74M) | (4.68M) | 1.07M |
| Other Working Capital | (29K) | 1.6M | 788K | 7.91M | 2.46M |
| Other Non-Cash Items | 6.61M | 272K | 290K | (4.77M) | (6.36M) |
| Operating Cash Flow | (27.53M) | (42.25M) | (73.46M) | (93.93M) | (180.39M) |
| Capital Expenditures | (68K) | (151K) | (89K) | (505K) | (933K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (386.63M) | (849.59M) |
| Sales of Investments | 0 | 0 | 0 | 94.8M | 456.22M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (68K) | (151K) | (89K) | (292.33M) | (394.3M) |
| Debt Repayment | (4.58M) | 0 | 0 | 28.99M | 0 |
| Common Stock Issued | 68K | 53.5M | 199.08M | 187.3M | 472.83M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 4.58M | 95.48M | 40.3M | 2.02M | 578K |
| Financing Cash Flow | 89.93M | 148.98M | 239.38M | 218.31M | 473.41M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 62.33M | 106.58M | 165.83M | (167.94M) | (101.29M) |
| Free Cash Flow | (27.6M) | (42.4M) | (73.55M) | (94.43M) | (181.33M) |
Disc Medicine, Inc.
NASDAQ:IRON
Intrinsic Alpha fair value
Locked
Current Price
$77.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.